Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the results from the Phase 1b CodeBreaK 101 study of Amgen's Lumakras (Sotorasib) combined with Vectibix (Panitumumab), for treating patients with colorectal cancer

Ticker(s): AMGN

Who's the expert?

Institution: Florida Cancer Specialists

Board certified medical oncologist and hematologist
Manages 20 patients with colorectal cancer
Extensive experience in Blood Disorders

Interview Goal

This call will focus on results from the Phase 1b CodeBreaK 101 study regarding Sotorasib combined with Panitumumab which shows a confirmed objective response rate of 30% in patients with chemo-refractory metastatic colorectal cancer.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.